ADVFN ADVFN

Hot Features

Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
Janux Therapeutics Inc

Janux Therapeutics Inc (JANX)

14.15
0.45
(3.28%)
終了 6月18日 5:00AM
14.15
0.00
( 0.00% )
プレマーケット: 5:50PM

Janux Therapeutics Inc (JANX) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

主要統計と詳細

通貨
14.15
( - )
買値
13.95
売値
14.30
出来高
762
0.00 日の範囲 0.00
12.12 52 週間の範囲 35.34
時価総額
前日終値
14.15
始値
-
最終取引時間
19:19:38
財務取引量
-
VWAP
-
平均取引量 (3 か月)
US$ 1,032,167
発行済株式数
60,984,354
配当利回り
PER
-7.37
1 株当たり利益 (EPS)
-1.84
歳入
13.73M
純利益
-114.48M

Janux Therapeutics Inc について

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company’s cl... Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company’s clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California. 詳細を表示

セクター
Healthcare
業界
Biotechnology & Life Sciences
ウェブサイト
本社
San Diego, United States
設立
2026
Janux Therapeutics Inc is listed in the Healthcare sector of the ナスダック市場 with ticker JANX. The last closing price for Janux Therapeutics was US$14.15. Over the last year, Janux Therapeutics shares have traded in a share price range of US$ 12.12 to US$ 35.34.

Janux Therapeutics currently has 60,984,354 shares in issue. The market capitalisation of Janux Therapeutics is US$862.93 million. Janux Therapeutics has a price to earnings ratio (PE ratio) of -7.37.

JANX 最新ニュース

期間 †前日比前日比 %始値高値安値平均出来高VWAP
11.017.6864535768613.1414.4613.0299824913.84656715CS
4-0.17-1.1871508379914.3214.8712.98581679914.00582633CS
120.523.8151137197413.6316.59512.98595377914.41384052CS
26-0.03-0.21156558533114.1816.59512.12116768414.07960647CS
52-8.8-38.344226579522.9535.3412.12117255418.73013798CS
1561.6313.019169329112.5271.715.6581809330.42385641CS
260-2.9053-17.034587488917.055371.715.6553494629.4728559CS

JANX - Frequently Asked Questions (FAQ)

What is the current Janux Therapeutics Inc share price?
The current share price of Janux Therapeutics Inc is US$ 14.15
How many Janux Therapeutics Inc shares are in issue?
Janux Therapeutics Inc has 60,984,354 shares in issue
What is the market cap of Janux Therapeutics Inc?
The market capitalisation of Janux Therapeutics Inc is USD 862.93M
What is the 1 year trading range for Janux Therapeutics Inc share price?
Janux Therapeutics Inc has traded in the range of US$ 12.12 to US$ 35.34 during the past year
What is the PE ratio of Janux Therapeutics Inc?
The price to earnings ratio of Janux Therapeutics Inc is -7.37
What is the cash to sales ratio of Janux Therapeutics Inc?
The cash to sales ratio of Janux Therapeutics Inc is 60.22
What is the registered address of Janux Therapeutics Inc?
The registered address for Janux Therapeutics Inc is 10955 Vista Sorrento Parkway, San Diego, California, 92130
What is the Janux Therapeutics Inc website address?
The website address for Janux Therapeutics Inc is www.januxrx.com
Which industry sector does Janux Therapeutics Inc operate in?
Janux Therapeutics Inc operates in the Biotechnology & Life Sciences sector

JANX 取引

さらに

取引は遅延しています

リアルタイムの取引を取得するには、アカウントをアップグレードしてください

リアルタイムにアップグレード

JANX Discussion

投稿を表示